{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gadoteridol", "query": { "intervention": "Gadoteridol" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gadoteridol&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T16:28:05.781Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05915728", "title": "A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Contrast Enhancement in Magnetic Resonance Imaging", "Non-central Nervous System Pathology" ], "interventions": [ { "name": "Gadoquatrane (BAY1747846)", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Gadoterate meglumine", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2023-07-24", "completion_date": "2024-06-01", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Indian Wells", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05915728" }, { "nct_id": "NCT00660543", "title": "MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Brain Glioblastoma" ], "interventions": [ { "name": "Gadolinium", "type": "DRUG" }, { "name": "Ferumoxytol Non-Stoichiometric Magnetite", "type": "DRUG" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "OTHER" }, { "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging", "type": "OTHER" }, { "name": "Diffusion Weighted Imaging", "type": "OTHER" }, { "name": "MRI-Based Angiogram", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2006-12", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00660543" }, { "nct_id": "NCT01613417", "title": "Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Brain Disease" ], "interventions": [ { "name": "gadoteridol", "type": "DRUG" }, { "name": "gadobutrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bracco Diagnostics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2012-08", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-07-01", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 1, "location_summary": "Teaneck, New Jersey", "locations": [ { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01613417" }, { "nct_id": "NCT03396822", "title": "Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2018-09-24", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03396822" }, { "nct_id": "NCT03750188", "title": "Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Central Nervous System Diseases", "Central Nervous System Neoplasms" ], "interventions": [ { "name": "ProHance", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bracco Diagnostics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "2 Years", "sex": "ALL", "summary": "1 Day to 2 Years" }, "enrollment_count": 125, "start_date": "2018-11-01", "completion_date": "2019-10-16", "has_results": false, "last_update_posted_date": "2020-01-23", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03750188" }, { "nct_id": "NCT04879628", "title": "Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "SAR441344 IV", "type": "DRUG" }, { "name": "placebo IV", "type": "DRUG" }, { "name": "SAR441344 SC", "type": "DRUG" }, { "name": "placebo SC", "type": "DRUG" }, { "name": "MRI contrast-enhancing preparations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 129, "start_date": "2021-06-07", "completion_date": "2027-08-23", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Tampa, Florida • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879628" }, { "nct_id": "NCT04373564", "title": "Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Motor Function", "Cognitive Function", "Contrast Media" ], "interventions": [ { "name": "Motor Tests", "type": "PROCEDURE" }, { "name": "Cognitive Tests", "type": "PROCEDURE" }, { "name": "Unenhanced-MRI of the brain", "type": "PROCEDURE" }, { "name": "Gadolinium Measurements", "type": "PROCEDURE" }, { "name": "Gadoxetate disodium", "type": "DRUG" }, { "name": "Gadobenate dimeglumine", "type": "DRUG" }, { "name": "Gadodiamide", "type": "DRUG" }, { "name": "Gadoterate meglumine", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 2076, "start_date": "2021-03-24", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04373564" }, { "nct_id": "NCT00600834", "title": "Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Insufficiency" ], "interventions": [], "intervention_types": [], "sponsor": "Bracco Diagnostics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 172, "start_date": "2008-02", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600834" }, { "nct_id": "NCT05915702", "title": "A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Contrast Enhancement in Magnetic Resonance Imaging", "Central Nervous System Pathology" ], "interventions": [ { "name": "Gadoquatrane (BAY1747846)", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Gadoterate meglumine", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2023-07-24", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 8, "location_summary": "Indian Wells, California • Orange, California • Miami, Florida + 5 more", "locations": [ { "city": "Indian Wells", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Farmington Hills", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05915702" }, { "nct_id": "NCT01019486", "title": "Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease", "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Regadenoson myocardial perfusion imaging", "type": "DRUG" }, { "name": "Regadenoson MRI myocardial blood flow", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 26, "start_date": "2009-11", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2015-12-14", "last_synced_at": "2026-09-04T16:28:05.781Z", "location_count": 4, "location_summary": "Aurora, Colorado • Denver, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01019486" } ] }